Key Highlights
● The FDA placed a full clinical hold on ARD-101 in May 2026.
● Aardvark terminated the Phase 3 HERO trial and open-label extension in June 2026.
● Cash and investments were US$73.9 million, funding operations into late 2027.
● The second-quarter net loss was US$14.4 million, or US$0.66 per share.
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company whose common stock is listed on Nasdaq under the ticker AARD. It develops small-molecule therapies intended to suppress hunger in Prader-Willi syndrome (PWS) and in wider metabolic disease.
Trial termination and the FDA hold
The central issue is the future of ARD-101, the lead candidate for PWS hyperphagia. According to the company, it voluntarily paused its Phase 3 HERO trial and open-label extension (OLE) earlier in 2026. In May 2026 the US Food and Drug Administration placed a full clinical hold on the ARD-101 investigational new drug application, covering all previously ongoing studies, including HERO and the OLE. In June 2026 Aardvark terminated both trials and said it does not currently intend to resume them as designed.
Aardvark states that it remains in active discussions with the FDA to resolve the hold. It has not disclosed a timetable for lifting it.
Financial results for the quarter and half-year
All amounts are in US dollars and relate to the quarter ended 30 June 2026 unless stated. Research and development expenses were US$10.5 million, down from US$13.1 million a year earlier, mainly because external manufacturing, clinical and toxicology spending fell after the pause and hold. General and administrative expenses rose to US$4.6 million from US$2.7 million, reflecting higher personnel costs, bonuses, public company costs and US$0.5 million of severance linked to a June 2026 workforce reduction.
Total operating expenses were US$15.1 million. The net loss was US$14.4 million, or US$0.66 per share, effectively unchanged from the same quarter of 2025. For the six months, the net loss widened to US$36.0 million, or US$1.65 per share, from US$23.7 million, or US$1.36 per share, in the first half of 2025.
Cash position and runway
Cash, cash equivalents and short-term investments totalled US$73.9 million at 30 June 2026, compared with US$91.2 million at 31 March 2026 and about US$110.0 million at 31 December 2025. Total stockholders' equity was US$74.8 million and the accumulated deficit was US$151.9 million. There were 21,884,158 shares outstanding at the period end.
Management guides that existing cash and investments should fund operations into late 2027, compared with a previous expectation of mid-2027 given in May 2026. That runway is a management estimate based on current plans, and it could change if the company restarts or redesigns development.
Why it matters
For a company whose value rests largely on one programme, the combination of terminated pivotal trials, a full clinical hold and a smaller team marks a significant reset. Chief executive Tien Lee, M.D., said the focus is on establishing a clear path forward for ARD-101 in PWS. The company also paused ARD-201, a combination for obesity, in March 2026, and has not reported a restart or given any restart date.
Unblinded Data Could Decide ARD-101's Path After the Hold
As of its 11 August 2026 results release, the company expected to review unblinded data from HERO and the OLE in the third quarter of 2026 to assess efficacy and safety and decide next steps.






Please wait processing your request...